Rapafusyn Pharmaceuticals: A Leader in Non-Degrading Molecular Glue Drug Discovery
June 25, 2024, 3:35 am
Rapafusyn Pharmaceuticals, a Baltimore-based company, recently secured $28 million in Series A funding to advance its innovative non-degrading molecular glue drug discovery platform. Led by 3E Bioventures Capital and Proxima Ventures Ltd., with participation from Lapam Capital, this funding will propel the progress of Rapafusyn's pipeline of macrocyclic peptide-based non-degrading molecular glues. Founded by Professor Jun O. Liu, Rapafusyn is at the forefront of developing therapies for challenging or previously undruggable disease targets.
Rapafusyn Pharmaceuticals is revolutionizing drug discovery with its RapaGlue™ platform, which rapidly discovers non-degrading molecular glues. These molecular glues offer a promising solution for difficult-to-drug targets, paving the way for significant advancements in drug development. The company's innovative approach integrates the benefits of molecular glues with cyclic peptides, creating cell-permeable drug candidates that can target a broad range of membrane or intracellular targets.
Dr. Jun O. Liu, the scientific founder of Rapafusyn, is a pioneer in the field of non-degrading molecular glues. His groundbreaking discovery of the molecular glue mechanism has laid the foundation for Rapafusyn's innovative platform. Dr. Liu's vision for the company is to bring groundbreaking therapies to patients by systematically and efficiently screening for small molecule modulators beyond traditional drug discovery methods.
Investors in Rapafusyn, such as 3E Bioventures, Proxima Ventures, and Lapam Capital, are confident in the company's potential to address unmet medical needs and discover transformational medicines. These investors recognize the value of Rapafusyn's non-degrading molecular glue platform and its ability to effectively drug challenging or undruggable disease targets.
Rapafusyn Pharmaceuticals is dedicated to developing transformational medicines that enhance patient care and address high unmet medical needs. With its innovative RapaGlue™ platform, the company is poised to make significant contributions to the field of drug discovery and development. For more information, visit rapafusyn.com or contact Heather Lavin at hlavin@rapafusyn.com.
Rapafusyn Pharmaceuticals is revolutionizing drug discovery with its RapaGlue™ platform, which rapidly discovers non-degrading molecular glues. These molecular glues offer a promising solution for difficult-to-drug targets, paving the way for significant advancements in drug development. The company's innovative approach integrates the benefits of molecular glues with cyclic peptides, creating cell-permeable drug candidates that can target a broad range of membrane or intracellular targets.
Dr. Jun O. Liu, the scientific founder of Rapafusyn, is a pioneer in the field of non-degrading molecular glues. His groundbreaking discovery of the molecular glue mechanism has laid the foundation for Rapafusyn's innovative platform. Dr. Liu's vision for the company is to bring groundbreaking therapies to patients by systematically and efficiently screening for small molecule modulators beyond traditional drug discovery methods.
Investors in Rapafusyn, such as 3E Bioventures, Proxima Ventures, and Lapam Capital, are confident in the company's potential to address unmet medical needs and discover transformational medicines. These investors recognize the value of Rapafusyn's non-degrading molecular glue platform and its ability to effectively drug challenging or undruggable disease targets.
Rapafusyn Pharmaceuticals is dedicated to developing transformational medicines that enhance patient care and address high unmet medical needs. With its innovative RapaGlue™ platform, the company is poised to make significant contributions to the field of drug discovery and development. For more information, visit rapafusyn.com or contact Heather Lavin at hlavin@rapafusyn.com.